A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
Condition: Obesity · Overweight · Sponsor: Novo Nordisk A/S
About this study
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
This description comes directly from the study's public registry record.
Talk to the study team
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Altasciences Clinical LA, Inc. | Cypress, California, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07710768